相关实验视频
Updated: Jul 18, 2025
07:32
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
4.1K
在心力衰竭中微生物群相关代谢物的最新进展
Sepiso K Masenga1,2, Joreen P Povia1, Propheria C Lwiindi1
1HAND Research Group, School of Medicine and Health Sciences, Mulungushi University, Livingstone Campus, Livingstone 10101, Zambia.
Biomedicines
|August 26, 2023
概括
肠道微生物群代谢物通过调节关键细胞通路,显著影响心力衰竭的发展. 本综述详细介绍了这些代谢物如何促进或保护心力衰竭的进展.
科学领域:
- 心血管医学 心血管医学
- 微生物组研究 微生物组研究
- 代谢学 代谢学 代谢学
背景情况:
- 心力衰竭 (HF) 是严重不良事件的主要危险因素,包括心脏骤停,器官衰竭和死亡率.
- 肠道微生物群及其代谢物越来越被认为是心力衰竭病变的关键参与者.
- 现有文献强调了特定肠道微生物代谢物在HF发育中的日益重要.
研究的目的:
- 审查和总结当前关于肠道微生物群代谢物在心力衰竭发病的作用的证据.
- 阐明这些代谢物影响HF发育的潜在机制.
- 突出肠道代谢物在心血管和代谢疾病中的有害和有益作用.
主要方法:
- 全面的文献搜索和近期研究的综合.
- 分析涉及HF中的肠道微生物群衍生代谢物的机制.
- 确定这些代谢产物调节的关键信号通路.
主要成果:
- 特定的肠道微生物群衍生代谢物,包括短链脂肪酸,胆汁酸,分支链氨基酸和三甲基胺N氧化物 (TMAO),促进HF.
- 这些代谢物调节关键信号通路,如NF-κB,BNIP3,NLRP3炎症体和PERK.
- 其他肠道代谢产物在HF和相关疾病中表现出有益作用.
结论:
- 肠道微生物群的代谢物在心力衰竭的发病过程中起着关键作用,通过多种分子机制起作用.
- 准肠道微生物群及其代谢物是心力衰竭的潜在治疗策略.
- 对肠道代谢物双重作用的进一步研究可以促进心血管和代谢疾病的管理.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:29Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463